3rd November 2023

Simbec-Orion and biotx.ai launch strategic partnership to de-risk early-stage drug development with AI supported clinical trial design

LONDON, Oct. 26, 2023 /PRNewswire/ — Simbec-Orion, a full-service mid-size CRO, and biotx.ai, a developer of AI-enabled causal modelling for drug development, have announced their strategic partnership to bring AI-powered insights and predictive models to support data-driven clinical trial design.

Simbec-Orion, a specialist in oncology, rare disease, and clinical pharmacology studies, has over 45 years’ experience supporting biotech and small to mid-sized drug development companies with complex early-stage clinical development in highly competitive and specialist patient populations.

Fabrice Chartier, CEO at Simbec-Orion, commented:

“We are delighted to announce our strategic partnership with biotx.ai. biotx.ai’s data-driven predictions will offer our clients a cost-effective way to generate additional data to support their clinical development strategy, by utilising causal AI models to predict clinical trial outcomes and using these insights to inform clinical trial design.”

biotx.ai’s causal AI technology accurately simulates the outcomes of clinical trials using their extensive human genetic database, which contains 3.3 million cases spanning over 12,000 diseases, each with a full phenotype analysis. The accuracy of their causal AI has been demonstrated by successfully predicting the outcomes of eight different COVID-19 trials and has since been replicated across a range of indications and therapeutic areas.

Joern Klinger, CEO at biotx.ai, commented on the potential causal models offer when applied to clinical drug development:

“Causal models at scale enable drug development: For a given drug we find all mechanisms and diseases causally affected by it. We find the best indication for our client’s drug, provide evidence for the absence of specific side effects compared to competing compounds, and, most importantly, evidence for the efficacy of their compounds in humans. For several of our clients this has been instrumental to successful fundraising for their phase 2 trials.”

On the value of utilising AI-powered causal models to secure funding, Fabrice Chartier adds: “It is a highly competitive environment for biotech companies. Investors are demanding more data, and being more selective with the projects they choose to fund. We support clients at those crucial early development stages, using our knowledge and experience to help inform their clinical development and corporate strategy. Offering our clients an opportunity to gather data on predicted clinical trial outcomes, before reaching the clinic, is a valuable tool to demonstrate a drug’s true potential to investors. With this technology, we can also provide input endpoints and protocol design to maximise the chance of delivering a successful study.”

To learn more about Simbec-Orion’s capabilities and experience, visit www.simbecorion.com